- Home
- EWTX vs JFR Comparison
EWTX vs JFR Comparison
Compare EWTX & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- JFR
- Stock Information
- Founded
- EWTX 2017
- JFR 2004
- Country
- EWTX United States
- JFR United States
- Employees
- EWTX N/A
- JFR N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- EWTX Health Care
- JFR Finance
- Exchange
- EWTX Nasdaq
- JFR Nasdaq
- Market Cap
- EWTX 1.2B
- JFR 1.1B
- IPO Year
- EWTX 2021
- JFR N/A
- Fundamental
- Price
- EWTX $14.30
- JFR $8.26
- Analyst Decision
- EWTX Buy
- JFR
- Analyst Count
- EWTX 8
- JFR 0
- Target Price
- EWTX $39.63
- JFR N/A
- AVG Volume (30 Days)
- EWTX 932.9K
- JFR 621.7K
- Earning Date
- EWTX 08-07-2025
- JFR 01-01-0001
- Dividend Yield
- EWTX N/A
- JFR 11.31%
- EPS Growth
- EWTX N/A
- JFR N/A
- EPS
- EWTX N/A
- JFR N/A
- Revenue
- EWTX N/A
- JFR N/A
- Revenue This Year
- EWTX N/A
- JFR N/A
- Revenue Next Year
- EWTX N/A
- JFR N/A
- P/E Ratio
- EWTX N/A
- JFR N/A
- Revenue Growth
- EWTX N/A
- JFR N/A
- 52 Week Low
- EWTX $10.60
- JFR $7.61
- 52 Week High
- EWTX $38.12
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- EWTX 41.90
- JFR 50.69
- Support Level
- EWTX $14.87
- JFR $8.28
- Resistance Level
- EWTX $15.68
- JFR $8.40
- Average True Range (ATR)
- EWTX 0.67
- JFR 0.05
- MACD
- EWTX -0.02
- JFR -0.01
- Stochastic Oscillator
- EWTX 15.25
- JFR 17.65
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.